Clinical trial
Screening Protocol to Evaluate Acid Alpha Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease for Potential Inclusion in Future Clinical Studies With Myozyme (Alglucosidase Alfa)
NCT00113035 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Screening Protocol to Evaluate Acid Alpha Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease for Potential Inclusion in Future Clinical Studies With Myozyme (Alglucosidase Alfa)
- Lead sponsor
- Genzyme, a Sanofi Company
- Phase
- Observational
- Overall status
- Completed
- Start date
- May 31, 2005
- Completion date
- October 31, 2005
- Enrollment
- 60
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
pompe disease